CDH3 may be a targert gene in biological therapy of colorectal cancer: P133

    loading  Checking for direct PDF access through Ovid


Aim:Assessment of alteration of CDH3 genes expression depending on colorectal cancer stage and its usefulness in diagnostics and therapy.Method:Specimens were collected from 28 patients (14 female and 14 male), who were operated for colorectal cancer. Analysis was performed using microarrays. mRNA was collected from adenocar-cinoma and macroscopically healthy tissue.Results:Agglomerative hierarchical clustering of normalized mRNA levels has shown four groups with statistically different gene expression. The control group was divided into two groups, the first was appropriate control (C1), the second (C2) had the geneticproperties of the tumor tissue without histological changes. The other two groups were: LSC (Low Stage Cancer) and HSC (High Stage Cancer). The statistically significant decrease in expression was observed in C1 versus LSC (P = 0.001), and C1 versus HSC (P = 0.000), as well as in C2 versus HSC (P = 0.000) and LSC versus HSC (P = 0.000). There were no CDH3 gene expression alterations in C2 versus LSC, and C1 versus C2 group.Conclusion:The level of CDH3 increases with colorectal cancerprogression, which mayprove itsproduct P-cadherin, as a potential target in biological target therapy, which corresponds with other authors' results. The lack of difference in its expression for C1 and C2 groupsprobably excludes this method in distinguishing molecular aberrations in macroscopically healthy tissue.

    loading  Loading Related Articles